Home Authors Posts by staff

staff

94 POSTS 0 COMMENTS

Innovation and technology at the service of the pharma industry

0

The pharmaceutical industry is experiencing a period of unprecedented transformation, characterised by the adoption of advanced technologies and the automation of production processes. In this scenario, LAST Technology stands out globally in the design and production of process equipment for the pharmaceutical and biopharmaceutical sectors and for research laboratories. The company’s mission is clear: to develop cutting-edge solutions for infection prevention, actively contributing to the protection of public health. We talked about it with Massimo Castellarin, President and CEO of LAST Technology.

The development of LAST Technology is firmly linked to research and innovation. How so?
Research and development are the pillars on which LAST Technology bases its growth strategy. The company actively collaborates with the main pharmaceutical and biopharmaceutical industries, developing customised solutions to meet the unmet and increasingly complex needs of the market. LAST Technology’s innovative approach translates into customised machinery, equipped with advanced automation and integrated technologies, capable of combining increasingly complex processes. One of the distinctive elements of the R&D strategy is the integration of commercial components and software that guarantees reliability, flexibility in the development of tailor-made solutions and remote control of equipment via centralised servers, tablets and smartphones. This approach allows optimising production processes and minimising intervention and maintenance times, increasing the overall reliability of the machines.

What are the latest innovations you offer?
LAST Technology is constantly engaged in the development of new technological solutions to improve pharmaceutical production processes. Among the main innovations introduced by the company we can mention: the use of a ketone (acetone) to remove the most resistant dirt from pharmaceutical active ingredients; ‘combo’ solutions that integrate washing and sterilisation in a single process; combined sterilisation systems using superheated water and steam for solids and liquids; low temperature sterilisation with ethylene oxide or hydrogen peroxide for heat-sensitive components; ATEX hot air drying machines for potentially explosive solid products. LAST Technology is a reliable and competent partner in the evolution towards the ‘automatic factory’, an increasingly widespread model in the pharmaceutical industry. In this sense, the company has developed innovative software based on market technologies and widely recognised communication protocols. This allows the integration of all LAST Technology process machines within the company domain, ensuring greater efficiency and connectivity.

Innovation in the proposal, but also in the optimisation of internal production processes.
LAST Technology has implemented an advanced computerised system to improve production efficiency and order management, making the management of the product life cycle more effective and optimised, from the Concept Design phase to C&Q. Thanks to the adoption of a PLM (Product Lifecycle Management) software platform, the company is able to interconnect all business functions, from product conception to marketing. The integration of PLM has reduced order management times by 20-30%, improving collaboration between the various departments. The use of mobile computer workstations in the assembly and testing areas allows internal staff and visiting customers to quickly access the technical documentation of the job order. This has significantly improved business efficiency, reducing time and enhancing the control of integrated processes in quality management. The project is part of the company’s computerisation strategy, supporting growth through the integration of Business Process Management, company know-how, data and documents.

Sustainability is an important value for you. What initiatives are you undertaking?
LAST Technology’s commitment to sustainability is realised through a business model based on the creation of shared value. The company has aligned its strategy with the United Nations Sustainable Development Goals (SDGs), adopting practices aimed at reducing environmental impact and promoting corporate social responsibility. The main sustainability initiatives include reducing emissions by 50% by 2024 thanks to energy efficiency and the installation of a 515 kWh photovoltaic system; implementing carbon neutrality policies by 2030; promoting an inclusive and stimulating work environment, enhancing the talent and creativity of employees. Knowledge of stakeholder needs and market dynamics also guides us in developing collaborations beyond sector boundaries, integrating economic growth, social well-being and sustainability. In doing so, we not only pursue our corporate objectives, but also actively contribute to collective progress. LAST Technology, in line with its Sustainability Policy, today takes a further step in the process of building shared value by obtaining the Silver Medal rating from EcoVadis.

A global reference
LAST Technology looks to the future with a clear strategy of innovation and internationalisation. The company aims to become a global leader in the sector, combining advanced technologies and process automation, according to the philosophy of ‘thinking globally and acting locally’. In this sense, Artificial Intelligence will play a key role in the company’s evolution.

Meeting market needs with creativity and quality

0

Alsystems’ journey began in San Casciano Val di Pesa (Florence – Italy) in 1991, when the company started to develop automation systems for various types of machinery as a pure third-party supplier. The Florentine company offered a wide range of solutions for many different industrial sectors, from filling and closing lines for the pharmaceutical and cosmetics industries to other sectors. «For over 25 years – CEO Goffredo Ruffini told us – our machines have handled a wide range of products: gels, creams, granules, powders for exams and diagnostics, infusion and ophthalmic liquids, syrups, nasal and oral sprays, homeopathic products and disinfectants. We offer filling and capping machines or complete turnkey systems specifically for the pharmaceutical, biomedical and parapharmaceutical sectors. We have about ten models that differ in terms of characteristics, operating speed and type of bottles and our strong point is that we carry out every phase internally, from design to testing, so as to guarantee our machines for 24 months. Customisation is a key word. Our strong point is the ability to design and build each machine around the real needs of the customer, right from the first contact. This approach allows us to provide solutions that perfectly match production needs and to establish an ongoing relationship with users, before the sale and throughout all the subsequent phases up to after-sales, which is an integral part of our way of working». Having an in-house technical department allows the company to follow every detail of the project, guaranteeing full control over quality. The company can therefore offer a 24-month warranty on all its machines. A clear sign of trust and reliability that for Alsystems is a natural choice, the result of in-depth knowledge of the components produced and how they work.

Hercules

The advantage of versatility

From the 90s to the present day, Alsystems has grown to a workforce of 20 and a production capacity that varies according to the type and size of the machines, on average 15-18 units every year. If customisation and quality are among the company’s outstanding prerogatives, versatility and reliability are what allow its models to stand out and «effectively cover a wide variety of sectors», Ruffini observed. «If I had to identify a star of the Alsystems portfolio, I would choose the Pegasus capping and filling machine. It’s aimed at the chemical-pharmaceutical and parapharmaceutical industries, but can be adapted to a wide range of applications and has been developed to handle bottles with capacities ranging from the smallest to volumes of one litre. In the single index version it can produce up to 3,000 pieces per hour; in the double index version it can produce up to 6,000 pieces per hour. Therefore it is suitable for different types of job, to meet a wide range of production requirements». The company also operates in the field of high-speed rotary presses for small formats with an output of up to 240 pieces per minute with the Hercules model. This is highly appreciated in the food supplement sector because it is equipped with sensors, volumetric dosing systems and, on request, cameras for quality control. It can handle bottles, test tubes, small bottles, with closures ranging from screw caps to droppers and pipettes, and competes well with the competition by focusing on technological quality. «With its multiple filling system – explained the CEO – Hercules has won acclaim in Italy and abroad».

Pegasus

The robot to come

Alsystems is also an export success, given that its machines can be found all over Europe, as well as in Mediterranean countries such as Egypt, Tunisia, Jordan and some Asian countries, thanks to a network of dedicated agents and representatives. At the same time, investments in R&D continue. «Currently – the interviewee said – the idea is to introduce a new generation of robots for movement management and machine enslavement. A series of targeted tests are underway with the aim of helping us understand how they can be used in practice. The fine tuning should be completed by the end of the year and from then on we will try to study the needs of customers to understand which ones might be interested in it. Innovation could find a place among the producers of parapharmaceuticals and pharmaceuticals that together represent more than half of Alsystems’ total turnover. Another significant slice of sales is in the chemical sector, where the Auriga series for large formats has proven its worth. Together with the products, the supplier is also very keen to offer services, which are also made possible thanks to the push towards digitalisation. «All our machines – explains Ruffini – can be connected to a network for remote assistance directly from our headquarters. For on-site maintenance technicians and end users, remote support is an advantage and we guarantee it by default at no additional cost. In addition, all machines can be equipped with specific modules for interconnection to ERPs to monitor batches and orders together with the progress of work for reporting purposes or to receive indications of work batches directly from the management system». Finally, a certain amount of attention is paid to reducing consumption. «We are conducting studies and analyses – concludes Ruffini – although further reducing energy requirements on engines that do not exceed 2 kW is not easy. Although Alsystems machines are by nature energy efficient, we always try to integrate them with engines with the highest possible performance».

Pegasus and Hercules

Pegasus is a versatile rotary machine for filling and capping. It can handle containers from 1 to 1,000 ml, with an hourly production of 500 to 6,000 pieces. It can handle containers with a maximum diameter of 82 mm and a maximum output of 100 pieces per minute. It has a stainless steel frame and is highly customisable from a technical point of view. The high-performance Hercules rotary machine, on the other hand, has a production speed of 240 pieces per minute with advanced volumetric dosing and quality control functions. It adapts to a wide variety of bottles and capping systems and is equipped with different types of sensors to ensure high-quality production in every area or phase of work.

From Mediterranean science, nutraceutical solutions for cardiovascular well-being

0

Esserre was founded with a clear vision: to promote well-being through Mediterranean nutrition. Established in 2013, the company stands out for its scientific and responsible approach to nutraceuticals. Every product is the result of research, technology, and environmental care. Its core values? Quality of life, sustainability, accessible innovation, and social responsibility. Esserre selects high-value ingredients from short supply chains and transforms them into effective nutraceuticals thanks to its in-house laboratory and certified quality systems. The goal is simple yet ambitious: to make science accessible and create tangible solutions that support a healthy lifestyle, through formulations inspired by the principles of the Mediterranean diet and validated by scientific studies.

Europe’s heart under pressure: the urgency of more effective prevention

According to international health bodies such as the World Health Organization and the European Society of Cardiology, cardiovascular diseases are the leading cause of death in Europe, accounting for about 1/3 of all deaths. MedTech Europe, European trade association representing the medical technology industry, highlights some key figures: over 13 million people affected each year and 1.7 million deaths. Cardiovascular deseases strike early, across gender and geography, yet public awareness of cardiovascular health remains low, while the burden on healthcare systems continues to grow. The Council of the European Union has recently called for strengthened prevention efforts, focusing on screening, equitable access to care, and health literacy. In this context, the integration of a healthy lifestyle with targeted nutritional support becomes a strategic approach. This is where nutraceuticals can play a concrete role in managing cardio-metabolic health profiles.

Redulen Cholesterol: a targeted response with Mediterranean roots

To address the growing need for validated formulations, Esserre developed Redulen® Cholesterol: a dietary supplement designed to support cardiovascular health. Its patented international formula combines Brumex® (bergamot extract), Nopalis® (prickly pear extract), phytosterols, and vitamin B1, and is free from monacolin K.Bergamot, cultivated in Calabria, is rich in flavonoids, powerful antioxidants found abundantly in the fruit. Several studies in scientific literature have highlighted its activity in cholesterol regulation. Nopalis®, from the young pads of prickly pear cactus of Sicily, is a source of soluble fibers that modulate nutrient absorption. Phytosterols help maintain normal blood cholesterol levels, while vitamin B1 supports heart function.Esserre clinical studies confirm the properties of the ingredients in the formula in managing normal lipid levels: a reduction in total cholesterol, LDL and TG, along with an increase in HDL. A sustainable and evidence-based solution, Redulen® Cholesterol is now one of the most innovative responses to the growing demand for cardiovascular support, fully aligned with European health priorities.

Via Fliaminia Nuova, 260
00191 Roma (Italy)
Ph: +39 06 39736623
info@esserrepharma.it
www.esserrepharma.com

The European single market strategy

0

On 21 May, the European Commission published its proposal for a Single Market Strategy, aimed at supporting companies in developing their businesses while providing greater protection for consumers.

More specifically, the Commission aims to remove ten barriers that still exist to trade between EU countries, which are considered “terrible” because of their impact on the overall competitiveness of the European bloc in an increasingly complex global environment. The proposal also plans to modernise rules in certain key sectors, including construction, postal services and parcel delivery, and to simplify regulations for many services. A new definition of small and medium-sized enterprises (SMEs) should enable them to enjoy certain benefits typically available to SMEs.

Furthermore, the digitisation of processes should make digital filing the norm for companies required to comply with European regulations.

The ten key actions to break down barriers

The European single market currently has 26 million businesses and 450 million consumers, generating 18% of the global economy and €18 trillion in value for European gross domestic product. However, the single market is characterised by low productivity (around 1%), which impacts European competitiveness. According to the European Commission, completing the single market would double its benefits. In particular, the services sector alone contributes 75% of the European Union’s GDP, but 60% of the barriers are the same as they were 20 years ago.

In this regard, one of the ten priorities identified by the legislation is the definition of the 28th company regime. Furthermore, the sharing of objectiveswith individual Member States should see each of them appoint a high-level representative for the single market, known as a “sherpa”, responsible for promoting the application of the new rules and ensuring that national legislation does not hinder the completion of the single market.

Other simplification measures should impact public procurement rules and speed up the recognition of professional qualifications. The standardisation regulation should also be reviewed, with the possibility for the Commission to establish common specifications where necessary. The digital product passport is one of the measures planned for the packaging and labelling of goods on the market, with the extension and harmonisation of extended producer responsibility schemes for the end-of-life management of products.

A European market surveillance authority could also be created and authorisations and certifications for cross-border services could be harmonised. Cross-border mobility of workers could be facilitated by the adoption of an electronic declaration for posted workers and the coordination of social security. Finally, the strategy plans to develop new tools against unjustified territorial restrictions on supply, beyond the situations prohibited under competition law.

Latest EFPIA data on access to innovative medicines in Europe

0

Only 46% of innovative medicines approved centrally in the period 2020-2023 (173 in total) were found to be available to European patients in 2024, according to data from the latest Patients W.A.I.T. Indicator report published by EFPIA. This figure is slightly lower than the previous survey (48%), which dates back to 2019. Much more pronounced than the same comparison period is the gap in medicines fully available under public reimbursement, which stood at 29% in 2004 vs 42% in 2019. On the other hand, the number of medicines available with restrictions increased from 6% in 2019 to 17% last year.

‘The EFPIA W.A.I.T. indicators have been published for more than two decades, and during this period there has been a collective failure across Europe to tip the balance for millions of patients,’said Nathalie Moll, Director General of EFPIA. It has long been recognised that there is no one-size-fits-all solution and that no single actor can solve the problem: strong will, country-specific solutions and a true alliance between EU policymakers, Member States and the pharmaceutical industry are needed to streamline bureaucracy, reduce duplication and ensure swift and pragmatic decisions on pricing and reimbursement that truly value and reward innovation‘.

Some more data on access to innovative medicines

The Patients W.A.I.T. Indicator study, conducted by Iqvia on behalf of EFPIA, was first published in 2004 and this year examined 36 different European countries.

The data showed an increase of about one month in the time needed to make innovative medicines available to European patients, from 531 days in the 2023 report to 578 in the latest release. High disparities in access (87%) between different European countries were also confirmed. From this point of view, Germany has the shortest time (128 days), while at the other end of the scale is Portugal (840 days). Significantly, the waiting time for access to cancer treatments also continues to increase, rising by 33 days since the last edition of the report.

The causes of unavailability

EFPIA has also published a second report, prepared by Charles River Associates, which explores the causes of the unavailability of innovative medicines in European countries, complementing the Patients W.A.I.T. Indicator.

There is no single cause at the root of the problem, but rather a mix of factors that can come into play at different points in the authorisation process. These include, for example, possible regulatory issues that slow down the MA granting process, delays in health technology assessment decisions or in price and reimbursement negotiations. Duplicate requests for evidence and the need to include products in different local formularies are other possible factors causing delays. These factors are particularly relevant in Italy, given the fragmentation of regional healthcare systems, which, according to the report, results in an average delay in access of 65 days (min 1 day – max 773 days) compared to the timing of decisions at national level.

Other points raised by the EFPIA document concern possible infrastructural difficulties in accessing new medicines, for example due to insufficient diagnostic capacity or staff specialisation, particularly for more complex products such as orphan medicines or advanced therapies.

HERA’s first three years of activity

Three years have passed since the creation of the Health Emergency Preparedness and Response Authority (HERA), one of the first initiatives born in response to the Covid-19 pandemic. The results obtained so far by HERA are summarised in a report published by the European Commission at the end of March 2025.

The Authority plays a central role in coordinating activities to improve preparedness and response capacities at the EU-level, including issues with the supply chains of critical medicines shortages. According to the report, the availability of a structure dedicated to medical countermeasures for pandemic preparedness and response helps to improve policy coherence and provides a clear EU added value in the area of health security, e.g. for joint procurement and stockpiling of medical countermeasures.

Recommended areas for future improvement of HERA’s activities should include synergies between HERA and other European institutions (e.g. ECDC, EMA, the Health Security Committee and the Advisory Committee on Public Health Emergencies), as well as an enhanced coordination and cooperation with Member States. Flexibility, optimisation of funding and effective communication of HERA’s activities are other key recommendations for the future.

Mediterranean Nutrition Science: pioneering the future of nutraceuticals

0

The pharmaceutical and nutraceutical industries are rapidly evolving, with growing demand for science-backed, sustainable solutions. Professionals in clinical research, regulatory affairs, quality control, and supply chain management seek innovative formulations that align with both patient needs and market trends. At the forefront of this transformation is Esserre, a leader in Mediterranean Nutrition Science, committed to developing clinically validated nutraceuticals. Thanks to its R&D center in Formello, Italy, and an open research network, Esserre creates solutions that blend Mediterranean extracts with pharmaceutical-grade ingredients. Recognized as the most effective strategy to prevent chronic diseases, the Mediterranean diet promotes longevity, holistic wellness and sustainability. Esserre enhances this approach by integrating advanced extraction techniques, phytocomplex characterization and a green supply chain, ensuring high-quality and science-backed formulations. Esserre’s nutraceutical portfolio addresses key health concerns with ready-to-market products, including:

  • Cardiometabolic Health: based on Brumex, a bergamot-derived extract clinically proven to support cholesterol and triglyceride reduction, backed by one clinical trial.
  • Immune & Energy Support: formulated with PunicaPLUS™, a pomegranate-derived extract with antioxidant activity.
  • Gut Health & Microbiota Balance: soluble fibers to support intestinal health.
  • Mental Wellness & Stress Reduction: a formula inspired by the principles of the Mediterranean diet, designed to support stress relief and cognitive function.

Esserre follows a pharma-inspired development model, ensuring scientific validation, regulatory compliance and market-readiness:

  • In-House R&D & Open Research Network – Proprietary scientific studies with leading universities.
  • Advanced Extraction & Formulation – Optimizing bioavailability.
  • Regulatory & Clinical Validation – Conducting preclinical and clinical trials under EU standards.
  • Sustainable Supply Chain – Traceable, clean-label production from botanical sourcing to final product.

As longevity and preventive healthcare gain global relevance, Esserre bridges the gap between pharma and nutraceuticals, delivering trusted, science-backed solutions.

AUDA-NEPAD is the new PIC/S associated partner

0

The ongoing initiative to strengthen regulatory capacity across the African continent took a significant step forward with the formal integration of the African Union Development Agency–New Partnership for Africa’s Development (AUDA-NEPAD) into the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This milestone reflects a broader commitment to enhancing the quality and safety standards of pharmaceuticals manufactured and distributed across Africa.

In January 2025, the PIC/S Committee officially granted AUDA-NEPAD the status of Associated Partner Organisation, recognizing its strategic role in supporting the development of the African Medicines Agency (AMA). The newly established partnership is underpinned by a cooperation agreement focused on aligning GMP (Good Manufacturing Practice) standards and quality systems for both finished pharmaceutical products and active pharmaceutical ingredients (APIs).

This agreement is designed to streamline the pre-accession and accession pathways to PIC/S for National Regulatory Authorities (NRAs) that are part of the AMA framework. It also aims to provide structured training programs for GMP inspectors, fostering the technical competence and regulatory oversight capabilities of national agencies across the continent.

Moreover, the collaboration is expected to serve as a catalyst for confidence-building measures among African NRAs, reinforcing their capacity to ultimately become full PIC/S Participating Authorities. In the long term, this alignment with international GMP standards will not only improve the regulatory harmonization across Africa but also bolster the global competitiveness and safety of medicines produced within the region.

This development marks a pivotal moment in Africa’s pharmaceutical sovereignty journey, signaling a deeper integration into the international regulatory community and a renewed focus on building resilient, quality-focused supply chains across the continent.

The Warsaw Declaration on the future of framework programmes

0

The Warsaw Declaration, released during the informal meeting of research ministers held on 10 and 11 March 2025 under the Polish presidency of the Council, contains the recommendations for the negotiations of the post-2027 Multiannual Financial Framework. Key points include the recognition of the long-standing importance of framework programmes as tools for fostering excellent science, technological development and innovation in the EU. The last two programmes also worked to expand transnational science and innovation cooperation within Europe and with like-minded countries.

The new FP10 should be designed so to provide long-term orientation to address the Union’s key challenges, secure a stable and predictable framework for the R&I community and strengthen the European Research Area. The Declaration recalls the pivotal role played by the European Research Council (ERC) and the European Innovation Council (EIC) and calls upon the Commission to preserve their independence and expand their role. EU research ministries also recall the provisions of the Treaty on the Functioning of the European Union, highlighting that the FP shall establish the scientific and technological objectives to be achieved, fix the maximum overall amount, and establish the detailed rules for Union financial participation.

The Declaration also underlines that the future FP should support excellent and impactful R&I in an open and fair competition. The request to the Commission is for an adequate budget matching the programme’s strategic role. In particular, none of the future programmes or instruments should be funded at the expense of the FP. Furthermore, funds should be allocated solely to research and innovation to maintain programme continuity and efficiency.

EU Commission, how to design a monitoring framework of the EU One Health Action Plans against AMR

The One Health approach, which integrates human, animal, and environmental health, plays a fundamental role in shaping numerous initiatives aimed at combating Antimicrobial Resistance (AMR). Recognizing the importance of a coordinated strategy, the European Commission has recently released a report detailing the design of a monitoring framework for the EU’s 2017 One Health Action Plan against AMR, as well as the 2023 Council Recommendation on strengthening EU efforts to tackle antimicrobial resistance through a One Health perspective.

The primary objective of this framework is to systematically track the implementation, progress, and overall impact of One Health initiatives, ensuring that EU actions addressing AMR are approached in a comprehensive and integrated manner. It encompasses a wide range of legislative and non-legislative measures that span across all 27 EU member states, along with Iceland and Norway. The study underpinning this framework was developed through extensive consultations with relevant stakeholders, the identification of key indicators from pre-existing data collection initiatives, and the proposal of additional indicators where necessary to fill gaps in monitoring efforts.

Given the evolving nature of policies and actions in the fight against AMR, the framework is expected to be adaptable over time. Future updates and refinements may be introduced to ensure its continued relevance and effectiveness as new challenges and developments emerge in the field of antimicrobial resistance.

(Source: European Commission)

Newsstand

  • NCF International n.1 - 2026 NCF International n.1 - 2026
  • NCF International n.2 - 2025 NCF International n.2 - 2025
  • NCF International n.1 - 2025 NCF International n.1 - 2025